| NCT00554606 | Novartis | Rheumatoid Arthritis | 2007-10-11 | PHASE2 |
| NCT01302795 | University of Zurich | Pyoderma Gangrenosum | 2011-02 | PHASE2 |
| NCT04365153 | The Cleveland Clinic|Novartis | COVID-19|SARS-CoV 2 | 2020-04-24 | PHASE2 |
| NCT01105507 | Novartis Pharmaceuticals | Cryopyrin Associated Periodic Syndrome | 2010-08 | PHASE3 |
| NCT01080131 | Novartis Pharmaceuticals | Acute Gout | 2010-03 | PHASE3 |
| NCT02296424 | Novartis Pharmaceuticals | Systemic Juvenile Idiopathic Arthritis (SJIA) | 2014-11-17 | PHASE3 |
| NCT00424346 | Novartis | Rheumatoid Arthritis | 2006-11 | PHASE2 |
| NCT00819585 | Novartis Pharmaceuticals | Gout | 2008-12 | PHASE2 |
| NCT00891046 | Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization | Systemic Juvenile Idiopathic Arthritis | 2009-09 | PHASE3 |
| NCT03775109 | Imperial College London|Novartis Pharmaceuticals | Alcoholic Hepatitis | 2019-02-12 | PHASE2 |
| NCT01362608 | Novartis Pharmaceuticals | Gouty Arthritis | 2011-06-20 | PHASE3 |
| NCT05080218 | Jeffrey Curtis|University of Alabama at Birmingham|University of Nebraska|University of Pennsylvania|AbbVie|Bristol-Myers Squibb|Novartis|Eli Lilly and Company|Pfizer|Illumination Health | Rheumatoid Arthritis|Psoriatic Arthritis|Spondylarthritis | 2021-11-15 | PHASE4 |
| NCT01029652 | Novartis Pharmaceuticals | Acute Gout | 2009-12 | PHASE3 |
| NCT00685373 | Novartis | Cryopyrin-Associated Periodic Syndromes|Familial Cold Autoinflammatory Syndrome|Muckle Wells Syndrome|Neonatal Onset Multisystem Inflammatory Disease | 2008-05 | PHASE3 |
| NCT01088880 | Novartis Pharmaceuticals | Familial Mediterranean Fever | 2010-04 | PHASE2 |
| NCT05641831 | Uma Borate | Clonal Cytopenia of Undetermined Significance | 2023-02-06 | PHASE2 |
| NCT00487825 | Novartis | Rheumatoid Arthritis | 2007-03 | PHASE2 |
| NCT02396212 | Novartis Pharmaceuticals | Systemic Juvenile Idiopathic Arthritis | 2015-05-07 | PHASE3 |
| NCT04028245 | Columbia University|Novartis | Carcinoma, Renal Cell | 2019-08-15 | EARLY_PHASE1 |
| NCT00991146 | Novartis Pharmaceuticals | Cryopyrin-associated Periodic Syndromes|Familial Cold Autoinflammatory Syndrome|Muckle-Wells Syndrome|Neonatal Onset Multisystem Inflammatory Disease | 2009-10 | PHASE3 |
| NCT00886769 | Novartis Pharmaceuticals|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Southwest Pediatric Nephrology Study Group | Systemic Juvenile Idiopathic Arthritis | 2009-07 | PHASE3 |
| NCT00770601 | Novartis Pharmaceuticals|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NOMID|CINCA Syndrome | 2009-01-26 | PHASE3 |
| NCT00605475 | Novartis | Type 2 Diabetes Mellitus | 2007-12 | PHASE2 |
| NCT01250171 | Novartis Pharmaceuticals | Dry Eye | 2010-11 | PHASE2 |
| NCT03631199 | Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 2018-12-21 | PHASE3 |
| NCT01327846 | Novartis Pharmaceuticals | Atherosclerosis | 2011-04-11 | PHASE3 |
| NCT04795466 | Novartis Pharmaceuticals | Mild Cognitive Impairment|Alzheimer Disease | 2021-10-28 | PHASE2 |
| NCT03064854 | Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 2017-05-24 | PHASE1 |
| NCT04239157 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Novartis | Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory Myelodysplastic Syndrome | 2020-08-25 | PHASE2 |
| NCT02911857 | Novartis Pharmaceuticals | Periodic Fevers Syndrome | 2016-10-03 | PHASE3 |
| NCT02059291 | Novartis Pharmaceuticals | Hereditary Periodic Fevers | 2014-06-27 | PHASE3 |
| NCT06691217 | Massachusetts General Hospital|National Institutes of Health (NIH)|Broad Institute of MIT and Harvard|Yale University | Vascular Inflammation|ASCVD|ASCVD Management | 2026-04-01 | PHASE2 |
| NCT01431638 | Novartis Pharmaceuticals | Acute Gouty Arthritis | 2011-08-25 | PHASE3 |
| NCT05984602 | NYU Langone Health | Pancreatic Cancer | 2023-07-14 | PHASE1 |
| NCT01635127 | University of Zurich | Chronic Idiopathic Urticaria | 2012-06 | PHASE2 |
| NCT00947427 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes|Preservation of Insulin Secretion|Newly Diagnosed Type 1 Diabetes|Canakinumab in Type 1 Diabetes | 2010-10 | PHASE2 |
| NCT01170936 | Charite University, Berlin, Germany|Novartis Pharmaceuticals | Urticaria|Vasculitis | 2010-07 | PHASE2 |
| NCT03447769 | Novartis Pharmaceuticals | Non-Small Cell Lung Cancer | 2018-03-16 | PHASE3 |
| NCT02334748 | Novartis Pharmaceuticals | Systemic Juvenile Idiopathic Arthritis|Hereditary Periodic Fevers | 2014-11-03 | PHASE3 |
| NCT01148797 | Novartis Pharmaceuticals | Colchicine Resistant+Intolerant Familial Mediterranean Fever | 2010-12 | PHASE2 |
| NCT03742349 | Novartis Pharmaceuticals | Triple Negative Breast Cancer (TNBC) | 2019-01-31 | PHASE1 |
| NCT05237713 | University of Leipzig|Novartis Pharmaceuticals | Anemia|Myelodysplastic Syndromes | 2022-04-26 | PHASE2 |
| NCT03968419 | Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 2019-11-05 | PHASE2 |
| NCT00581945 | Novartis | Chronic Obstructive Pulmonary Disease | 2007-01 | PHASE1|PHASE2 |
| NCT05725343 | Mario Negri Institute for Pharmacological Research|Novartis Pharmaceuticals | Lung Cancer | 2022-02-03 | PHASE3 |
| NCT04229004 | Pancreatic Cancer Action Network | Metastatic Pancreatic Cancer|Metastatic Pancreatic Adenocarcinoma | 2020-01-31 | PHASE3 |
| NCT04717635 | Novartis Pharmaceuticals | Adult Onset Still´s Disease | 2021-03-30 | PHASE3 |
| NCT04348448 | AUSL Romagna Rimini | COVID-19 | 2020-02-01 | |
| NCT02775994 | Rabin Medical Center | Periodic Fever | 2016-08 | PHASE1 |
| NCT07138898 | NYU Langone Health | Rheumatic Disease | 2025-09 | PHASE2 |
| NCT04810611 | Novartis Pharmaceuticals | Myelodysplastic Syndromes | 2021-06-18 | PHASE1 |
| NCT01589029 | PD Dr. med. Stephan Michels|Novartis|University Hospital, Zürich | Proliferative Diabetic Retinopathy | 2012-04 | PHASE1 |
| NCT03626545 | Novartis Pharmaceuticals | Non-Small-Cell Lung | 2019-01-23 | PHASE3 |
| NCT00900146 | Novartis | Diabetes Mellitus, Type 2 | 2009-04 | PHASE2|PHASE3 |
| NCT04814368 | Novartis Pharmaceuticals | Knee Osteoarthritis | 2021-08-27 | PHASE2 |
| NCT02756650 | Novartis Pharmaceuticals | Behcet Disease | 2016-06-23 | PHASE2 |
| NCT01390350 | Charite University, Berlin, Germany|Novartis Pharmaceuticals | Schnitzler Syndrome | 2011-07 | PHASE2 |
| NCT02272946 | Priscilla Hsue, MD|Massachusetts General Hospital | HIV|Cardiovascular Disease | 2015-09 | PHASE2 |
| NCT01276522 | Radboud University Medical Center|Novartis | Schnitzler Syndrome | 2011-01 | PHASE2 |
| NCT01805960 | University Hospital, Basel, Switzerland | Atrial Fibrillation | 2013-06 | PHASE2 |
| NCT04362813 | Novartis Pharmaceuticals | Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia | 2020-04-30 | PHASE3 |
| NCT00798369 | Novartis | Acute Gout | 2008-11 | PHASE2 |
| NCT00927810 | Novartis Pharmaceuticals | Gouty Arthritis | 2009-06-05 | PHASE2 |
| NCT05535738 | Wei-Che Ko | Skin Inflammation|Allergic Contact Dermatitis | 2022-11-15 | PHASE2|PHASE3 |
| NCT02204293 | Charite University, Berlin, Germany | Adult-Onset Still?s Disease | 2012-06-21 | PHASE2 |
| NCT04510493 | University Hospital, Basel, Switzerland|Novartis|Swiss National Science Foundation | Coronavirus Infection|Diabetes Mellitus, Type 2 | 2020-10-23 | PHASE3 |
| NCT03936894 | Children´s National Research Institute|Foundation to Eradicate Duchenne | Duchenne Muscular Dystrophy | 2019-05-01 | PHASE1|PHASE2 |
| NCT04905316 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 2021-05-21 | PHASE2 |
| NCT04581343 | Pancreatic Cancer Action Network|Novartis Pharmaceuticals | Metastatic Pancreatic Ductal Adenocarcinoma | 2020-11-02 | PHASE1 |
| NCT01303380 | Novartis Pharmaceuticals | Mevalonate Kinase Deficiency | 2011-03 | PHASE2 |
| NCT05401578 | University Hospital, Basel, Switzerland | Postprandial Hypoglycemia | 2023-04-17 | PHASE3 |
| NCT00487708 | Novartis Pharmaceuticals | NALP3 Mutation | 2005-01 | PHASE2 |
| NCT00663169 | Novartis | Arthritis, Gouty | 2008-04 | PHASE2 |
| NCT01068860 | Novartis | Type 2 Diabetes Mellitus|Impaired Glucose Tolerance | 2010-02 | PHASE2 |
| NCT04476706 | Novartis Pharmaceuticals | Cytokine Release Syndrome in COVID-19-induced Pneumonia | | |
| NCT06038526 | Peter Shields | Cigarette Smoking-Related Carcinoma|Lung Carcinoma | 2024-03-11 | PHASE2 |
| NCT04798339 | H. Lee Moffitt Cancer Center and Research Institute|Novartis Pharmaceuticals | Myelodysplastic Syndromes | 2021-03-30 | PHASE1|PHASE2 |
| NCT00889863 | Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization | Systemic Juvenile Idiopathic Arthritis With Active Flare | 2009-07 | PHASE3 |
| NCT02980263 | Novartis Pharmaceuticals | Kawasaki Disease | 2016-11-15 | PHASE2 |
| NCT01731990 | Novartis Pharmaceuticals | Peripheral Artery Disease | 2012-10-30 | PHASE2 |
| NCT01676948 | Novartis Pharmaceuticals|PRINTO + PRCSG | Systemic Juvenile Idiopathic Arthritis | 2013-01 | PHASE3 |
| NCT04789681 | M.D. Anderson Cancer Center | Lung Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 | 2021-07-20 | PHASE2 |
| NCT01245127 | Universitaire Ziekenhuizen KU Leuven | Schnitzler Syndrome | 2011-05 | PHASE2 |
| NCT06838143 | Novartis Pharmaceuticals | Hereditary Periodic Fever Syndromes|Cryopyrin-associated Periodic Syndromes (CAPS)|Colchicine Resistance Familial Mediterranean Fever (crFMF)|TNF Receptor Associated Periodic Syndrome (TRAPS)|Hyper-IgD Syndrome + Mevalonate Kinase Deficiency (HIDS+MKD)|Systemic Juvenile Idiopathic Arthritis (sJIA) | 2025-03-29 | |